The role of sphingosine 1-phosphate in inflammation and cancer

Advances in Biological Regulation

Volumn 54, Issue 1, 2014, Pages 121-129

  Pyne, Nigel J ^a   Ohotski, Jan ^a   Bittman, Robert ^b   Pyne, Susan ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANIMAL; ARTICLE; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; NEOPLASM;

ANIMALS; HUMANS; INFLAMMATION; LYSOPHOSPHOLIPIDS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOSINE;

EID: 84893415078     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.08.005     Document Type: Article

References (58)

1. Alvarez S.E., Milstien S., Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endo Metabol 2007, 18:300-307.
2. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine 1-phosphate is a missing co-factor for the E3 ligase TRAF2. Nature 2010, 465:1084-1088.
3. Baek D.J., MacRitchie N., Pyne N.J., Pyne S., Bittman R. The synthesis of selective inhibitors sphingosine kinase 1. Chem Comm 2013, 49:2136-2138.
4. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897.
5. Choi J.W., Gardell S.E., Herr D.R., Rivera R., Lee C.W., Noguchi K., et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011, 108:751-756.
6. Deng W.G., Nishizaki M., Fang B., Roth J.A., Ji L. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun 2007, 355:993-999.
7. Fischer D.I., McLennen A.G. Correlation of intracellular diadenosine triphosphate (Ap3A) with apoptosis in Fhit-positive HEK 293 cells. Cancer Lett 2008, 259:186-191.
8. French K.J., Schrecengost R.S., Lee B.D., Zhuang Y., Smith S.N., Eberly J.L., et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003, 63:5962-5969.
9. French K.J., Zhuang Y., Maines L.W., Gao P., Wang W., Beljanski V., et al. Pharmacology and anti-tumour activity of ABC294640, a selective inhibitor of sphingosine kinase-2. JPharmacol Exp Ther 2010, 333:129-139.
10. Hammad S.M., Crellin H.G., Wu B.X., Melton J., Anelli V., Obeid L.M. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat 2008, 85:107-114.
11. Idzko M., Hammad H., van Nimwegen M., Kool M., Müller T., Soullié T., et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. JClin Invest 2006, 116:2935-2944.
12. Ji L., Fang B., Yen N., Fong K., Minna J.D., Roth J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated Fragile Histidine Triad (FHIT) gene overexpression. Cancer Res 1999, 59:3333-3339.
13. Jolly P.S., Bektas M., Olivera A., Gonzalez-Espinosa C., Proia R.L., Rivera J., et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. JExp Med 2004, 199:959-970.
14. Kawamori T., Osta W., Johnson K.R., Pettus B.J., Bielawski J., Tanaka T., et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006, 20:386-388.
15. Kawamori T., Kaneshiro T., Okumura M., Maalouf S., Uflacker A., Bielawski J., et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009, 23:405-414.
16. Kihara A., Anada Y., Igarashi Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. JBiol Chem 2006, 281:4532-4539.
17. Kitano M., Hla T., Sekiguchi M., Kawahito Y., Yoshimura R., Miyazawa K., et al. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum 2006, 54:742-753.
18. Kohno M., Momoi M., Oo M.L., Paik J.H., Lee Y.M., Venkataraman K., et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006, 26:7211-7223.
19. Lai W.Q., Irwan A.W., Goh H.H., Howe H.S., Yu D.T., Valle-Oñate R., et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. JImmunol 2008, 181:8010-8017.
20. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
21. Lim K.G., Tonelli F., Li Z., Lu X., Bittman R., Pyne S., et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. JBiol Chem 2011, 286:18633-18640.
22. Lim K.G., Sun C., Bittman R., Pyne N.J., Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal 2011, 23:1590-1595.
23. Liu Q., Rehman H., Shi Y., Krishnasamy Y., Lemasters J.J., Smith C.D., et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One 2012, 7:e41834.
24. Liu Z., MacRitchie N., Pyne S., Pyne N.J., Bittman R. Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors and activators. Bioorg Med Chem 2013, 21:25013-32510.
25. Long J.S., Edwards J., Watson C., Tovey S., Mair K., Schiff R., et al. Sphingosine kinase 1 induces tolerance to human Epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol Cell Biol 2010, 30:3827-3841.
26. Loveridge C., Tonelli F., Leclercq T.M., Lim K.G., Long J.S., Berdyshev E., et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. JBiol Chem 2010, 285:38841-38852.
27. Matsuura M., Imayoshi T., Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 2000, 22:323-331.
28. Nayak D., Huo Y., Kwang W.X., Pushparaj P.N., Kumar S.D., Ling E.A., et al. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 2010, 166:132-144.
29. Ohotski J., Long J.S., Orange C., Elsberger B., Mallon E., Doughty J., et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2012, 106:1453-1459.
30. Ohotski J., Edwards J., Elsberger B., Watson C., Orange C., Mallon E., et al. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int J Cancer 2013, 132:605-616.
31. Oskeritzian C.A., Alvarez S.E., Hait N.C., Price M.M., Milstien S., Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood 2004, 111:4193-4200.
32. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. JBiol Chem 2000, 275:21797-21800.
33. Paugh S.W., Paugh B.S., Rahmani M., Kapitonov D., Almenara J.A., Kordula T., et al. Aselective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008, 112:1382-1391.
34. Pettus B.J., Bielawski J., Porcelli A.M., Reames D.L., Johnson K.R., Morrow J., et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J 2003, 17:1411-1421.
35. Pichiorri F., Palumbo T., Suh S.S., Okamura H., Trapasso F., Ishii H., et al. Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 2008, 4:815-824.
36. Pitson S.M., Xia P., Leclercq T.M., Moretti P.A., Zebol J.R., Lynn H.E., et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. JExp Med 2005, 201:49-54.
37. Pyne N.J., Pyne S. Sphingosine 1 phosphate and cancer. Nature Rev Cancer 2010, 10:489-503.
38. Pyne S., Pyne N.J. Translational aspects of sphingosine 1-phosphate biology. Trends Mol Med 2011, 17:463-472.
39. Pyne N.J., Pyne S. Sphingosine 1-phosphate is the missing link between inflammation and colon cancer. Cancer Cell 2013, 23:5-7.
40. Pyne N.J., Tonelli F., Lim K.G., Long S., Edwards J., Pyne S. Targeting sphingosine kinase 1 in cancer. Adv Biol Regul 2012, 52:31-38.
41. Samy E.T., Meyer C.A., Caplazi P., Langrish C.L., Lora J.M., Bluethmann H., et al. Cutting edge: modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate. JImmunol 2007, 179:5644-5648.
42. Sard L., Accornero P., Tornielli S., Delia D., Bunone G., Campiglio M., et al. Tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999, 96:8489-8492.
43. Schnute M.E., McReynolds M.D., Kasten T., Yates M., Jerome G., Rains J.W., et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012, 444:79-88.
44. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997, 94:6658-6663.
45. Snider A.J., Kawamori T., Bradshaw S.G., Orr K.A., Gilkeson G.S., Hannun Y.A., et al. Arole for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 2009, 23:143-152.
46. Takabe K., Paugh S.W., Milstien S., Spiegel S. 'Inside-out' signalling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008, 60:181-195.
47. Tonelli F., Lim K.G., Loveridge C., Long J., Pitson S.M., Tigyi G., et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010, 22:1536-1542.
48. Trapasso F., Pichiorri F., Gaspari M., Palumbo T., Aqeilan R.I., Gaudio E., et al. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. JBiol Chem 2008, 283:13736-13744.
49. Van Brocklyn J.R., Jackson C.A., Pearl D.K., Kotur M.S., Snyder P.J., Prior T.W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: role of sphingosine kinase isoforms in growth of glioblastoma cell lines. JNeuropathol Exp Neurol 2005, 64:695-705.
50. Vartanian A., Prudovsky I., Suzuki H., Dal Pra I., Kisselev L. Opposite effect of cell differentiation and apoptosis on AP3A/AP4A ratio in human cell cultures. FEBS Lett 1997, 415:160-162.
51. Wadgaonkar R., Patel V., Grinkina N., Romano C., Liu J., Zhao Y., et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol 2009, 296:L603-L613.
52. Wang F., Tan W., Guo D., He S. Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Eur J Pharmacol 2007, 573:230-240.
53. Wang Z., Min X., Xiao S.H., Johnstone S., Romanow W., Meininger D., et al. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure 2013, 21:798-809.
54. 3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010, 177:2205-2215.
55. Watson D.G., Tonelli F., Alossaimi M., Williamson L., Chan E., Gorshkova I., et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell Signal 2013, 25:1011-1017.
56. Wu W., Mosteller R.D., Broek D. Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 2004, 24:7359-7369.
57. Xia P., Gamble J.R., Rye K.A., Wang L., Hii C.S., Cockerill P., et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A 1998, 95:14196-14201.
58. Yoshimoto T., Furuhata M., Kamiya S., Hisada M., Miyaji H., Magami Y., et al. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. JImmunol 2003, 171:1352-1359.